Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine

CONCLUSION: Fremanezumab (225 mg) and Galcanezumab (120 mg) may be the best clinical protocol after a comprehensive assessment.PMID:34281473 | DOI:10.1080/01616412.2021.1940672

Source: Neurological Research - July 20, 2021 Category: Neurology Authors: Min Shi Jun Guo Zhaoying Li Honghui Sun Xuhong Yang Dongdong Yang Huan Zhao Source Type: research